Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00168181
Status:
COMPLETED
Last Update Posted:
2011-04-18
First Post:
2005-09-09
Brief Title:
Trial Comparing Oral Pilocarpine Salagen Versus Submandibular Salivary Gland Transfer Protocol For the Prevention of Radiation XRT Induced Xerostomia in Head and Neck Cancer Patients
Sponsor:
Alberta Health services
Organization:
AHS Cancer Control Alberta
Study Overview
Official Title:
A Phase III Randomized Trial Comparing Oral Pilocarpine Salagen Versus Submandibular Salivary Gland Transfer Protocol For the Prevention of Radiation XRT Induced Xerostomia in Head and Neck Cancer Patients
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None